Krystal Biotech price to free cash flow KRYS
Market value divided by free cash flow over the last twelve months, since 2024.
- Today, Nov 2, 2026
- 34.0×
- Peer median
- 22.5×
Krystal Biotech's price to free cash flow is 34.0× as of Nov 2, 2026.
The median for 10 biotech stocks of a similar size is 22.5×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 34.0× | 34.0× | 49.9× |
| 2025 | 44.2× | 21.6× | 79.1× |
| 2024 | 78.9× | 78.9× | 98.9× |
Against its peers
Companies in Biotechnology nearest Krystal Biotech's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| KRYSKrystal Biotech | 34.0× |
| RGENRepligen | 87.2× |
| TECHBIO-TECHNE | 43.3× |
| HALOHalozyme Therapeutics | 18.2× |
| NBIXNeurocrine Biosciences | 17.0× |
| EXELExelixis | 14.8× |
| ALNYAlnylam Pharmaceuticals | 26.7× |
| INCYIncyte | 12.7× |
| UTHRUnited Therapeutics | 23.7× |
| ADMAAdma Biologics | 21.3× |
| VCELVericel | 33.6× |
| Peer median | 22.5× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Krystal Biotech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.